MEK2

Isoforms Recommended:	MEK2

By Targets:	Apoptosis (7) Aryl Hydrocarbon Receptor (1) Aurora Kinase (1) Autophagy (8) ERK (3) FLT3 (1) Influenza Virus (2) Isotope-Labeled Compounds (1) MEK (17) Mitophagy (2) PDGFR (1) Pim (1) PROTACs (1) VEGFR (1)
By Research Areas:	Cancer (18)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-12058

AZD8330

5+ Cited Publications

ARRY-424704; ARRY-704
MEK Cancer

AZD8330 (ARRY-424704) is a potent, uncompetitive MEK1/MEK2 inhibitor, with an IC₅₀ of 7 nM.
HY-15437

SL327

5+ Cited Publications

MEK Cancer

SL327 inhibits MEK1 and MEK2, with IC₅₀ values of 180 nM and 220 nM, respectively.
HY-14719

RO4987655

4 Publications Verification

CH4987655
MEK Cancer

RO4987655 is an orally active and highly selective MEK inhibitor with an IC₅₀ of 5.2 nM for inhibition of MEK1/MEK2.

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

SL327 5+ Cited Publications	MEK	Cancer
SL327 inhibits *MEK1* and *MEK2, with IC₅₀* values of 180 nM and 220 nM, respectively.

RO4987655 4 Publications Verification CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective *MEK* inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-130602

MS432	PROTACs MEK	Cancer
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for *MEK1* and *MEK2. MS432 displays good plasma exposure in mice, exhibiting DC₅₀* values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively .

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

HY-18086

TCS PIM-1 1 3 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive Pim-1 kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) .

HY-10999

Trametinib 150+ Cited Publications GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis ^[2].

HY-12031A

U0126 Maximum Cited Publications 331 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[2] .

HY-12031

U0126-EtOH Maximum Cited Publications 331 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor ^[2] .

HY-10999S

Trametinib-d4	MEK Autophagy Apoptosis	Cancer
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999A

Trametinib (DMSO solvate) 150+ Cited Publications GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)	MEK Apoptosis	Cancer
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis ^[2].

HY-10999S1

Trametinib-13C6	MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S2

Trametinib-13C,d3 GSK1120212-¹³C,d₃; JTP-74057-¹³C,d₃	Isotope-Labeled Compounds MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-18955

BI-847325	MEK Aurora Kinase Apoptosis	Cancer
BI-847325 is an ATP competitive dual inhibitor of *MEK* and aurora kinases (AK) with IC₅₀ values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10254

Mirdametinib 80+ Cited Publications PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive *MEK* inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts ^[2] .

HY-12028

PD98059 280+ Cited Publications	MEK ERK Aryl Hydrocarbon Receptor Autophagy	Cancer
PD98059 is a potent and selective *MEK* inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of *MEK, thereby preventing the activation of MEK1* (IC₅₀ of 2-7 µM) and *MEK2* (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a *ERK1/2* signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy ^[2] .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107417

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

Cat. No.	Compare	Product Name	Species	Source

HY-P74755

	MEK2 Protein, Human (sf9, GST) Dual specificity mitogen-activated protein kinase kinase 2; MAPKK 2; MEK 2	Human	Sf9 insect cells
	MEK2, a pivotal kinase in cellular signaling, catalyzes the simultaneous phosphorylation of a threonine and a tyrosine residue within the Thr-Glu-Tyr sequence of MAP kinases. This enzymatic activity results in the activation of ERK1 and ERK2 MAP kinases, contributing to the intricate network of cellular responses. MEK2's role extends to the activation of BRAF, a process regulated by its interaction with KSR1 or KSR2. Binding to KSR1 or KSR2 facilitates the release of inhibitory intramolecular interactions within KSR1 or KSR2, promoting the dimerization of KSR1 or KSR2 with BRAF and subsequent BRAF activation. This mechanism highlights MEK2's significance in orchestrating signaling cascades critical for cellular functions. MEK2 Protein, Human (sf9, GST) is the recombinant human-derived MEK2 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of MEK2 Protein, Human (sf9, GST) is 400 a.a., with molecular weight of ~66 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10999S

Trametinib-d4
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S1

Trametinib-13C6
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

HY-10999S2

Trametinib-13C,d3
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P83314

MEK2 Antibody (YA3059) MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein kinase kinase 2; MAP kinase kinase 2; MAPKK 2; ERK activator kinase 2; MAPK/ERK kinase 2; MEK 2	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

MEK2

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products